Figure 10.

The effect of nepalolide A on the degradation of IκB-α. C6 glioma cells were treated with 5 μg ml⁻¹ LPS/100 units ml⁻¹ IFN-γ (LPS/IFN-γ) or 5 ng ml⁻¹ TNF-α/5 ng ml⁻¹ IL-1β/100 units ml⁻¹ IFN-γ (mixed cytokines) in the presence or absence of nepalolide A (2–10 μM) for 60 and 10 min, respectively (a). Astrocytes were treated with mixed cytokines plus or minus nepalolide A (2–10 μM) for 5 min (b). After treatment, cellular lysates were prepared and immunoblotting of intracellular IκB-α was performed. Results are means±s.d. (where large enough to be shown) from three independent experiments, and expressed relative to the cells at zero time. Significant differences between control and nepalolide A-treated cells are indicated by ^*P<0.05; ^**P<0.01; and ^***P<0.001.